EmilyGGreengardMD

Pediatric Hematology & Oncology • Chapel Hill, NC

Associate Professor, Pediatrics University of North Carolina at Chapel Hill

Join to view full profile

Dr. Greengard is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Greengard's full profile

Already have an account?

Office
170 Manning Dr
1185A Houpt Physicians Office Building
Chapel Hill, NC 27514
Phone+1 919-966-1179

Fax+1 612-365-8101

Education & Training

Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2007 - 2010
McGaw Medical Center of Northwestern UniversityResidency, Pediatrics, 2004 - 2007
Saint Louis University School of MedicineClass of 2004

Certifications & Licensure

MN State Medical License 2010 - 2025
NC State Medical License 2024 - 2025
SD State Medical License Active through 2021
PA State Medical License 2007 - 2010
IL State Medical License 2004 - 2008
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
Active, not recruiting
Phase 3
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
Recruiting
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 1
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12
Completed
Phase 2
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2013 Jan 31
Completed
Phase 1, Phase 2
MIBG for Refractory Neuroblastoma and Pheochromocytoma Start of enrollment: 2013 Dec 01
Suspended
Not Applicable
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Start of enrollment: 2013 Sep 03
Completed
Phase 1
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2014 Mar 28
Completed
Phase 1, Phase 2
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Start of enrollment: 2014 May 16
Completed
Phase 1, Phase 2
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Start of enrollment: 2014 Sep 01
Completed
Phase 1
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Start of enrollment: 2015 Dec 11
Completed
Phase 1
Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors Start of enrollment: 2018 Jan 31
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

41 citations
A phase I clinical study to evaluate safety of orally administered, genetically engineered Salmonella enterica serovar Typhimurium for canine osteosarcoma.
Sara E. Fritz, Michael S. Henson, Emily Greengard, Amber L. Winter, Kathleen Stuebner
Veterinary Medicine and Science. 2016-06-06
47 citations
Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).
Navin Pinto, Arlene Naranjo, Emily Hibbitts, Susan G. Kreissman, M. Meaghan Granger
European Journal of Cancer. 2019-05-01
21 citations
Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic la...
Emily Greengard, Yael P. Mosse, Xiaowei Liu, Charles G. Minard, Joel M. Reid
Cancer Chemotherapy and Pharmacology. 2020-12-01

Lectures

A phase I/II trial of VX15/2503 in children, adolescents, and young adults with relapsed or refractory solid tumors (ADVL1614).
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019

Press Mentions

New Treatment for Central Nervous System Tumors Enters Phase I Clinical TrialsJanuary 12th, 2021